We are live on ! Find out more
MG

Meditor Group Portfolio holdings

AUM $48.1M
1-Year Est. Return 38.67%
This Fund
S&P 500
This Quarter Est. Return
-3.67%
1 Year Est. Return
+38.67%
3 Year Est. Return
+41.15%
5 Year Est. Return
+72.2%
10 Year Est. Return
+1,065.64%
AUM
$446M
AUM Growth
-$30.5M
Cap. Flow
-$2.56M
Cap. Flow %
-0.57%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$2.56M

Sector Composition

Rank Sector Weight
1 Healthcare 95.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.9B
$314M 70.35%
12,841,798
– –
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
$99.6M 22.32%
2,679,835
– –
ALKS icon
3
Alkermes
ALKS
$8.82B
$12.4M 2.78%
750,000
– –
INDA icon
4
iShares MSCI India ETF
INDA
$6.71B
$10.8M 2.43%
320,000
– –
EPI icon
5
WisdomTree India Earnings Fund ETF
EPI
$2.02B
$9.44M 2.12%
400,000
– –
CLDX icon
6
Celldex Therapeutics
CLDX
$2.77B
– –
-196,846
Closed -$2.56M

Similar funds

BHCM
Boulder Hill Capital Management New York $47.9M AUM
VMV
Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return
BHH
Baker Hughes Holdings Houston, Texas $47.6M AUM 26.35% 1-Year Est. Return
LAMC
Lubert-Adler Management Company Philadelphia, Pennsylvania $49.3M AUM 17.46% 1-Year Est. Return
MAM
Miria Asset Management St. Julians, Malta $49.9M AUM 21.84% 1-Year Est. Return
BCM
BlueMar Capital Management Miami, Florida $49.9M AUM 28.76% 1-Year Est. Return
LOF
Lightspeed Opportunity Fund Menlo Park, California $50.1M AUM 53.1% 1-Year Est. Return
CLCM
Center Lake Capital Management West Palm Beach, Florida $45.8M AUM 58.23% 1-Year Est. Return

Meditor Group's Q3 2020 Portfolio in Review

As of Q3 2020, Meditor Group held 6 positions worth $446M, down 6.4% from $477M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Meditor Group's Q3 2020 filing shows 1 closed position. The largest sale was Celldex Therapeutics, an estimated $2.56M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier.

  • Meditor Group fully exited Celldex Therapeutics in Q3 2020, selling an estimated $2.56M.
  • Meditor Group's ten largest holdings make up 100% of its $446M portfolio in Q3 2020.
  • Meditor Group opened 0 new positions and closed 1 in Q3 2020.
  • Meditor Group's portfolio value fell 6.4% quarter-over-quarter to $446M.

Based on Meditor Group's 13F filing for Q3 2020, filed 19 Oct 2020.